Day One Biopharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia from Needham maintained a Buy rating on the stock and has a $16.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ami Fadia’s rating is based on several positive indicators for Day One Biopharmaceuticals. The company’s third-quarter earnings per share were better than expected, coming in at -$0.19 compared to the consensus estimate of -$0.30. This was achieved through slightly higher revenues and significantly lower research and development expenses, although there was a slight increase in selling, general, and administrative costs.
Additionally, the sales of Ojemda, one of the company’s key products, exceeded expectations by approximately 5%, driven by increased market share in the second-line market and strong patient access. The management has adjusted its full-year guidance to the higher end of the previous range, indicating confidence in continued performance. These factors combined suggest a positive outlook for the company’s stock, justifying the Buy rating.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $26.00 price target.